GlassScriptPhysician profile
Jonathan Grattan Bellew
NPI 1417103094
$9,725.23
in general payments reported to CMS, 2019-2025
26 companies · $2,794 in 2025
The $2,794 reported for 2025 was more than what 83% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $692 · 2020: $381 · 2021: $908 · 2022: $1,283 · 2023: $1,706 · 2024: $1,960 · 2025: $2,794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,828 · Education: $633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,827.68 |
| Education | $633.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,306.61 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,730.38 | 2019-2025 | Tremfya, Stelara, Remicade |
| Sun Pharmaceutical Industries INC. | $949.87 | 2021-2025 | Blu-U, Ilumya, Absorica Ld |
| Regeneron Healthcare Solutions, INC. | $690.93 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $532.62 | 2019-2025 | |
| Lilly USA, LLC | $449.27 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $434.66 | 2022-2025 | |
| Amgen INC. | $391.71 | 2020-2024 | Otezla, Enbrel |
| Leo Pharma INC. | $389.84 | 2022-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $379.48 | 2022-2025 | Nemluvio, Aklief |
| Genzyme Corporation | $315.37 | 2020-2025 | |
| Ucb, INC. | $278.08 | 2021-2025 | Bimzelx |
| Incyte Corporation | $243.70 | 2022-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $170.56 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $119.86 | 2021-2024 | Duobrii, Siliq |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.82 | 2022-2025 | Spevigo |
| Merz North America, INC. | $69.33 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $32.47 | 2025 | Sotyktu |
| Biofrontera INC. | $26.70 | 2023-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Journey Medical Corporation | $25.92 | 2022 | |
| Almirall LLC | $20.83 | 2022 | |
| Sanofi-Aventis U.S. LLC | $20.50 | 2020 | |
| Botanix Sb INC | $19.96 | 2025 | Sofdra |
| Dermira, INC. | $15.66 | 2021 | |
| Smith+Nephew, INC. | $14.74 | 2022 | |
| Dermavant Sciences, INC. | $13.36 | 2023 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Bellew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.